ストックスクリーナーアプリを入手
4.61
0.66%
0.03
アフターアワーズ：
4.61
前日終値:
$4.58
開ける：
$4.51
24時間の取引高:
982.52K
Relative Volume:
1.17
時価総額：
$473.93M
収益：
$380.79M
当期純損益:
$49.27M
株価収益率:
6.5857
EPS:
0.7
ネットキャッシュフロー:
$10.68M
1週間 パフォーマンス:
-13.35%
1か月 パフォーマンス:
+32.09%
6か月 パフォーマンス:
-31.19%
1年 パフォーマンス:
+143.92%
1日の値動き範囲:
$4.405
$4.82
1週間の範囲:
$4.405
$5.36
52週間の値動き範囲:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
名前
Amylyx Pharmaceuticals Inc
セクター
電話
617-683-0917
住所
43 THORNDIKE STREET, CAMBRIDGE
AMLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
4.61 | 473.93M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-07 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-11-18 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-03-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-03-08 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-03 | 開始されました | Robert W. Baird | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-24 | アップグレード | Goldman | Neutral → Buy |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-01-05 | 開始されました | BofA Securities | Buy |
| 2022-05-25 | 開始されました | Citigroup | Buy |
| 2022-04-01 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Amylyx Pharmaceuticals Inc (AMLX) 最新ニュース
Amylyx Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMLX) - Seeking Alpha
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) Target Price Raised by HC Wainwrig - GuruFocus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partnrs - Defense World
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Leerink Partners - Defense World
Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances - TipRanks
Amylyx Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Mariner LLC Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This Biotech Found Mid-Week Success Following Analyst Upgrade - The Globe and Mail
Amylyx Pharmaceuticals Shares Rise After Upgrade From Leerink - marketscreener.com
Amylyx Pharmaceuticals (AMLX) Rating Upgraded by Leerink Partner - GuruFocus
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences - BioSpace
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Leerink Partners Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Tower Research Capital LLC TRC Has $174,000 Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday - Defense World
Amylyx (AMLX) Upgraded as Avexitide Gains Momentum | AMLX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co. - Defense World
UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
This trade activity should not be overlooked: Amylyx Pharmaceuticals Inc (AMLX) - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Investor’s Delight: Amylyx Pharmaceuticals Inc (AMLX) Closes Strong at 5.11, Up 4.29 - DWinneX
Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment - Yahoo Finance
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycem - GuruFocus
Potential Price Increase for Amylyx Pharmaceuticals Inc (AMLX) After Recent Insider Activity - knoxdaily.com
Amylyx Pharmaceuticals Starts Dosing in Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment - marketscreener.com
Amylyx Pharmaceuticals Inc (AMLX) stock: A year of ups and downs - uspostnews.com
Amylyx (AMLX) Begins Phase 3 Trial for Post-Bariatric Hypoglycemia Treatment | AMLX Stock News - GuruFocus
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia - BioSpace
Amylyx starts Phase 3 trial for hypoglycemia treatment By Investing.com - Investing.com India
Amylyx starts Phase 3 trial for hypoglycemia treatment - Investing.com
Amylyx Pharmaceuticals Announces First Participant Dosed In Pivotal Phase 3 Lucidity Trial Of Avexitide In Post-Bariatric Hypoglycemia - marketscreener.com
Guggenheim Capital LLC Has $136,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Geode Capital Management LLC Grows Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
AMLX’s Stock Journey: What Investors Need to Know About Amylyx Pharmaceuticals Inc’s Performance - investchronicle.com
Amylyx Pharma Gearing Up For FDA Decision - RTTNews
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Amylyx Pharmaceuticals Inc (AMLX) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):